Updates

Craneware - Gain since main profile: 154%

February 2018

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Craneware, which supplies billing software analysis tools for the US healthcare sector, has issued an interim update to 31 December. Renewal rates by value continued at over 100% and there has been a significant new contract with one of the largest healthcare provider networks in the US. This contract is expected to deliver over US$16m of revenue in its five year term. As a consequence, Craneware suggests a growth guidance range for revenue and EBITDA of 15% to 18%. Net cash has climbed to over US$50m. Investec forecasts eps of 56.7 cents for the year to end June with 64.4 cents next year. My original buy was at 708p in November ‘15 when I described this as a bullet proof business and they now stand £10 h ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

GAME Digital - Solid peak trading

Joules - 6% upgrade after sensational Christmas

Craneware (September 2024)

Craneware - Growing pipeline of opportunities (October 2023)

Craneware (July 2019)

Craneware (August 2018)

Craneware - Two significant new contracts (March 2018)

Craneware - Bullet proof business (October 2016)

Craneware (August 2016)

Craneware - Big beneficiary of Obamacare (November 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X